NCIt definition : A humanized monoclonal antibody against the activated coagulation factor XIIa (FXIIa),
with potential anti-inflammatory and anticoagulant activities. Upon administration,
garadacimab targets and binds to FXIIa, blocking the activation of both the kallikrein-kinin
system and the intrinsic pathway of coagulation. Blocking the activation of the kallikrein-kinin
system may reduce inflammation as well as the production of bradykinin (BK). This
may prevent BK-driven edema in hereditary angioedema (HAE). Blocking the activation
of the intrinsic pathway of coagulation may lead to anti-coagulation. This may also
prevent or improve pulmonary edema not associated with HAE and improve the associated
decrease in blood oxygen levels.;